Illumina, Inc. (NASDAQ:ILMN) Position Lowered by Pacer Advisors Inc.

Pacer Advisors Inc. reduced its position in Illumina, Inc. (NASDAQ:ILMN) by 24.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,640 shares of the life sciences company’s stock after selling 7,553 shares during the quarter. Pacer Advisors Inc.’s holdings in Illumina were worth $3,159,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ILMN. AQR Capital Management LLC lifted its stake in Illumina by 390.9% during the second quarter. AQR Capital Management LLC now owns 75,561 shares of the life sciences company’s stock worth $7,887,000 after purchasing an additional 60,168 shares during the last quarter. Creative Planning lifted its position in shares of Illumina by 3.4% in the 2nd quarter. Creative Planning now owns 16,144 shares of the life sciences company’s stock worth $1,685,000 after buying an additional 525 shares during the last quarter. B. Riley Wealth Advisors Inc. boosted its holdings in shares of Illumina by 176.3% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company’s stock valued at $749,000 after buying an additional 4,579 shares during the period. Truist Financial Corp grew its position in shares of Illumina by 1.7% during the 2nd quarter. Truist Financial Corp now owns 62,840 shares of the life sciences company’s stock valued at $6,559,000 after buying an additional 1,075 shares during the last quarter. Finally, Cetera Investment Advisers grew its position in shares of Illumina by 25.8% during the 2nd quarter. Cetera Investment Advisers now owns 18,384 shares of the life sciences company’s stock valued at $1,919,000 after buying an additional 3,767 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on ILMN. Canaccord Genuity Group lifted their target price on Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research note on Tuesday, November 5th. TD Cowen increased their target price on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Royal Bank of Canada boosted their price target on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Barclays increased their price objective on shares of Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Finally, Citigroup lowered shares of Illumina from a “buy” rating to a “neutral” rating and reduced their target price for the company from $190.00 to $165.00 in a research note on Wednesday, December 11th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $165.63.

Illumina Price Performance

Shares of Illumina stock opened at $132.74 on Friday. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The stock has a market cap of $21.05 billion, a PE ratio of -13.33 and a beta of 1.11. The company’s 50-day moving average price is $138.97 and its two-hundred day moving average price is $135.03.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business’s quarterly revenue was down 3.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.33 earnings per share. As a group, sell-side analysts anticipate that Illumina, Inc. will post 4.13 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.